Seroatlas · Human Serome Atlas

NME9

Thioredoxin domain-containing protein 6

Also known as: NM23-H9, TXL-2, TXND6_HUMAN, TXNDC6

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q86XW9
Gene: NME9
Ensembl: ENSG00000181322
Chromosome: 3
Canonical length: 330 aa
Protein class: Predicted intracellular proteins
Subcellular location: Centriolar satellite,Cytosol
Quaternary structure: Homodimer

OverviewNCBI Gene

Predicted to enable nucleoside diphosphate kinase activity. Predicted to be involved in CTP biosynthetic process; GTP biosynthetic process; and UTP biosynthetic process. Predicted to be located in dynein axonemal particle. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

330 residues, UniProt reviewed canonical sequence.

>Q86XW9|NME9
     1  MGSRKKEIAL QVNISTQELW EEMLSSKGLT VVDVYQGWCG PCKPVVSLFQ KMRIEVGLDL
    61  LHFALAEADR LDVLEKYRGK CEPTFLFYAG GELVAVVRGA NAPLLQKTIL DQLEAEKKVL
   121  AEGRERKVIK DEALSDEDEC VSHGKNNGED EDMVSSERTC TLAIIKPDAV AHGKTDEIIM
   181  KIQEAGFEIL TNEERTMTEA EVRLFYQHKA GEEAFEKLVH HMCSGPSHLL ILTRTEGFED
   241  VVTTWRTVMG PRDPNVARRE QPESLRAQYG TEMPFNAVHG SRDREDADRE LALLFPSLKF
   301  SDKDTEAPQG GEAEATAGPT EALCFPEDVD

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NME9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.35
Highest tissue expression: 20 nTPM

Expression across tissuesHPA

Tissue

choroid plexus: 20 nTPM
fallopian tube: 17 nTPM
retina: 6.9 nTPM
hypothalamus: 6.5 nTPM
basal ganglia: 5.2 nTPM
hippocampal formation: 4.8 nTPM

Single-cell type

ependymal cells: 264 nCPM
choroid plexus epithelial cells: 171 nCPM
cardiomyocytes: 165 nCPM
respiratory ciliated cells: 160 nCPM
oligodendrocyte progenitor cells: 159 nCPM
epicardial cells: 109 nCPM

Immune cell

MAIT T-cell: 0.5 nTPM
naive CD4 T-cell: 0.4 nTPM
memory CD4 T-cell: 0.3 nTPM
classical monocyte: 0.2 nTPM
plasmacytoid DC: 0.2 nTPM
T-reg: 0.2 nTPM

Brain region

choroid plexus: 35 nTPM
cerebellum: 22 nTPM
medulla oblongata: 19 nTPM
midbrain: 19 nTPM
spinal cord: 15 nTPM
hypothalamus: 14 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.3
gnomAD pLI: 0
gnomAD missense Z: 0.96
DepMap mean gene effect: 0.05
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

nucleoside diphosphate kinase activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NME9 as an antibody target. Whether an autoantibody or antibody against NME9 could matter depends on whether native NME9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NME9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label NME9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...